Counterfeiters managed to get fakes of some of Roche's ($RHHBY) top-selling cancer drugs, including Herceptin and MabThera/Rituxan, into the European market this summer. This, among other issues, has motivated Roche's Genentech to have specialty distributors handle these recently conterfeited drugs, as well as Avastin. This decision has outraged some hospitals.
A debate has raged over the past couple of years over whether world governments are wasting money by stockpiling Roche's Tamiflu and GlaxoSmithKline's Relenza to help combat a potential flu epidemic. At issue is a tough question: Are the drugs effective enough to justify the estimated $2 billion spent to stockpile them?
On " 60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.
Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no...
One hospital chain has struck back at Roche's Genentech unit for switching its top 3 cancer treatments to specialty distributors. Ascension Health, a Roman Catholic-based group of more than 130 hospitals, is barring Genentech sales reps at the door.
Roche just can't win with the U.K.'s drug price watchdog, the National Institute for Health and Care Excellence (NICE). In August, the agency decided the company's heralded breast cancer drug Kadcyla was too expensive for the country's health system to cover. Now NICE has slapped Roche with a preliminary thumbs-down on Gazyvaro, its new drug to treat chronic lymphocytic leukemia (CLL).
HER2-positive breast cancer treatments already do pretty well for themselves, with Roche's Herceptin taking the No. 8 spot last year on the world's list of best-selling drugs. But according to a new report, their sales are about to jump--big time.
Roche's Genentech unit is getting some high-profile blowback from a change to its distribution model on three top cancer meds. Hospital and pharmacy executives claim the new regime--which restricts Avastin, Rituxan and Herceptin to a half-dozen specialty distributors--will cost them big money.
GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with GE Healthcare to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.
These days, even expensive cancer treatments don't necessarily deliver show-stopping study results when it comes to actually extending patients' lives. Roche's Perjeta is now a major departure from that trend.